ZTI-01 (fosfomycin for injection) in the treatment of hospitalized patients with complicated urinary tract infections. (8th March 2019)

• Record Type: Journal Article
• Authors: Burgos, Rodrigo M; Rodvold, Keith A
• Is Part Of: Future microbiology. Volume 14:Number 6(2019)
• Page Start: 461
• Page End: 475
• Publication Date: 2019-03-08
• Subjects: acute pyelonephritis -- antibiotics -- antimicrobial agents -- complicated urinary tract infection -- efficacy -- fosfomycin -- pharmacodynamics -- pharmacokinetics -- safety -- tolerability -- ZTI-01; Microbiology -- Research -- Periodicals; 616.9041
• DOI: 10.2217/fmb-2018-0303
• Languages: English
• ISSNs: 1746-0913

Abstract

Fosfomycin is a bactericidal antibiotic available since the 1970s whose intravenous formulation has been available in many countries outside the USA. Given the rise in drug-resistant bacteria, its introduction into the US market has become a necessity for addressing these organisms. This review provides an overview of the microbiology, clinical pharmacology and initial clinical experiences of the intravenous fosfomycin product (ZTI-01) that is undergoing clinical development in the USA for the treatment of complicated urinary tract infections and acute pyelonephritis.